Piribo: Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market”. http://www.piribo.com/publications/finance_investment/financial_markets_research_indevus_pharmaceuticals_sanctura_xr.html

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR's near-term potential.

Highlights
Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.

Scope
- Analyzes the commercial potential for IDEV's Sanctura XR, a recently-approved next-generation OAB agent
- Datamonitor interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR
Reasons to Purchase
- Understand the commercial potential for Sanctura XR in the treatment of OAB through in-depth analysis based on interviews with leading experts
- Anticipate likely changes in the future market dynamics for overactive bladder agents given the entry of a new market player

Contents
Summary
Indevus Pharmaceuticals
Overactive Bladder
Factors Affecting The Potential For Sanctura Xr
Sanctura Xr Forecast
Appendix

“Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_indevus_pharmaceuticals_sanctura_xr.html

Piribo Product ID: DAT546

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.